Changes in prostate-specific antigen and hormone levels following withdrawal of prolonged androgen ablation for prostate cancer

被引:0
作者
S Egawa
H Okusa
K Matsumoto
K Suyama
S Baba
机构
[1] Kitasato University School of Medicine,Department of Urology
来源
Prostate Cancer and Prostatic Diseases | 2003年 / 6卷
关键词
androgen ablation; testosterone; prostate-specific antigen; bone mineral density;
D O I
暂无
中图分类号
学科分类号
摘要
We conducted a study in order to characterize changes after withdrawal of androgen ablation (AA) for prostate cancer. AA was withdrawn in 38 Japanese patients with prostate cancer who had undergone this therapy for various periods. Patients were stratified into those who had undergone AA for less than 24 months (Group 1, n=12) and those with longer periods of AA (Group 2, n=26). Serial changes in hormones and prostate-specific antigen (PSA) were prospectively monitored following cessation of AA. The median durations of AA in the two groups were 8.5 and 54.5 months, respectively. Levels of total testosterone (T), luteinizing hormone and PSA increased significantly with time. At the end of 2 y, 30/38 patients (78.9%) had T levels above 50 ng/dl and 19/38 (50%) had levels above 320 ng/dl. Patients in Group 2 required significantly longer duration for T recovery. Complete T recovery is not always accompanied by rising PSA. Recovery of T levels is often slow following cessation of prolonged AA. Expression of PSA after AA is often variable and unpredictable. Thus, interpretation of outcomes in clinical trials incorporating AA needs caution and careful consideration.
引用
收藏
页码:245 / 249
页数:4
相关论文
共 23 条
[1]  
Huggins C(1941)Studies on prostatic cancer. I. The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 293-297
[2]  
Hodges CV(2000)A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men Jpn J Clin Oncol 30 21-26
[3]  
Egawa S(1993)Effects of intermittent androgen suppression on androgen-dependent tumours: apoptosis and serum prostate specific antigen Cancer 71 2782-2790
[4]  
Akakura K(1998)Contemporary hormonal management of advanced prostate cancer Oncology 12 499-505
[5]  
Moul JW(2002)Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma Cancer 94 362-367
[6]  
Pickles T(1997)Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 295-300
[7]  
Bolla M(1999)Serum testosterone-based luteinizing hormone-releasing hormone agonist redosing schedule for chronic androgen ablation: a phase I assessment Urology 54 694-699
[8]  
Oefelein MG(1999)Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer Urology 53 898-903
[9]  
Hall MC(2000)A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy J Urol 164 1891-1894
[10]  
Nejat RJ(1998)Time to normalization of serum testosterone after 3-month luteinizing hormone-releasing hormone agonist administered in the neoadjuvant setting: implications for dosing schedule and neoadjuvant study consideration J Urol 160 1685-1688